A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment

被引:40
作者
Durez, P
Toukap, AN
Lauwerys, BR
Manicourt, DH
Verschueren, P
Westhovens, R
Devogelaer, JP
Houssiau, FA
机构
[1] Catholic Univ Louvain, Clin Univ St Luc, Dept Rheumatol, B-1200 Brussels, Belgium
[2] Katholieke Univ Leuven, UZ Gasthuisberg, Dept Rheumatol, Louvain, Belgium
关键词
D O I
10.1136/ard.2003.012914
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To compare the short term clinical and biological effects of intravenous (IV) pulse methylprednisolone (MP) and infliximab (IFX) in patients with severe active rheumatoid arthritis (RA) despite methotrexate (MTX) treatment. Methods: Patients with active RA despite MTX treatment were randomly allocated to receive a single IV infusion of MP (1 g) or three IV infusions of IFX (3 mg/kg) on weeks 0, 2, and 6. Patients were "blindly'' evaluated for disease activity measures. Quality of life (QoL) was evaluated through the SF-36 health survey. Serum matrix metalloproteinase-3 (MMP-3) titres were measured at baseline, weeks 2 and 6. Results: Compared with baseline, significant improvement was noted in all activity measures, including serum C reactive protein (CRP) titres, in the IFX group only. At week 14, 6/9 (67%) and 4/9 (44%) IFX patients met the ACR20 and 50 response criteria, while this was the case in only 1/12 (8%) and 0/12 (0%) MP patients, respectively (p<0.05). None of the QoL scales improved with MP treatment, whereas some did so in the IFX group. Serum MMP-3 titres significantly decreased (41% drop) at week 6 in the IFX group, while no changes were seen in patients given MP. Conclusion: This short term randomised comparative study demonstrates that TNF blockade is better than MP pulse therapy in a subset of patients with severe refractory RA, with improvement in not only clinical parameters of disease activity but also biological inflammatory indices, such as serum CRP and MMP-3 titres.
引用
收藏
页码:1069 / 1074
页数:6
相关论文
共 25 条
  • [21] A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING A PULSE OF 1000 WITH 250 MG METHYLPREDNISOLONE IN RHEUMATOID-ARTHRITIS
    VISCHER, TL
    SINNIGER, M
    OTT, H
    GERSTER, JC
    [J]. CLINICAL RHEUMATOLOGY, 1986, 5 (03) : 325 - 326
  • [22] A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
    Weinblatt, ME
    Kremer, JM
    Bankhurst, AD
    Bulpitt, KJ
    Fleischmann, RM
    Fox, RI
    Jackson, CG
    Lange, M
    Burge, DJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) : 253 - 259
  • [23] Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
    Weinblatt, ME
    Keystone, EC
    Furst, DE
    Moreland, LW
    Weisman, MH
    Birbara, CA
    Teoh, LA
    Fischkoff, SA
    Chartash, EK
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (01): : 35 - 45
  • [24] CORTICOSTEROID PULSE THERAPY IN ACTIVE RHEUMATOID-ARTHRITIS
    WEUSTEN, BLAM
    JACOBS, JWG
    BIJLSMA, JWJ
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 1993, 23 (03) : 183 - 192
  • [25] The effects of pulse methylprednisolone on matrix metalloproteinase and tissue inhibitor of metalloproteinase-1 expression in rheumatoid arthritis
    Wong, P
    Cuello, C
    Bertouch, JV
    Roberts-Thomson, PJ
    Ahern, MJ
    Smith, MD
    Youssef, PP
    [J]. RHEUMATOLOGY, 2000, 39 (10) : 1067 - 1073